FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Core Viewpoint - The FDA has accepted Viatris' supplemental New Drug Application for MR-141 (phentolamine ophthalmic solution 0.75%) aimed at treating presbyopia, with a PDUFA goal date set for October 17, 2026, indicating progress in the company's innovative pipeline [1][2]. Group 1: Product Development - MR-141 is designed to treat presbyopia, a condition affecting approximately 90% of adults over 45 in the U.S., leading to blurred near vision and eye strain [1]. - The sNDA is supported by data from pivotal Phase 3 trials, VEGA-2 and VEGA-3, which met primary and key secondary endpoints without serious adverse events [1][2]. - Data from the VEGA-3 trial will be presented at upcoming ophthalmology meetings, highlighting the product's efficacy [1]. Group 2: Market Context - Presbyopia affects nearly 128 million people in the U.S., with a global estimate of 1.8 billion people affected in 2015, projected to rise to 2.1 billion by 2030 [1]. - Ryzumvi® is currently the only FDA-approved product for treating pharmacologically-induced mydriasis, and the sNDA seeks to expand its indication to include presbyopia [1][2]. Group 3: Company Overview - Viatris is positioned to bridge the gap between generics and brands, providing access to high-quality medicines for approximately 1 billion patients annually [1]. - The company operates globally with headquarters in the U.S. and centers in Pittsburgh, Shanghai, and Hyderabad, India [1].